Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon.

Bombesin-like peptides are uniformly thought to act as mitogens in cancer. Yet by studying human tissues, we have recently shown that bombesin and its mammalian homologue gastrin-releasing peptide act as morphogens, promoting tumor differentiation when aberrantly upregulated in colon cancer. In contrast, little is known about the bombesin-like peptide neuromedin B (NMB) and its receptor (NMB-R) in the human gastrointestinal tract. We therefore studied their presence and function in normal and malignant human colonic epithelia. Anti-NMB monoclonal antibodies were made against keyhole limpet hemocyanin (KLH)-conjugated human NMB, whereas anti-NMB-R antibodies were raised in rabbits against KLH-conjugated peptides corresponding to the third intracellular loop and COOH-terminal tail of the receptor protein. NMB antibody recognized two bands at approximately 1.2 kDa and approximately 1.5 kDa. NMB-R antibodies recognized a band at 80 kDa (predicted 43 kDa); whereas treatment with the deglycosylating agent peptide-N-glycosidase generated bands at 65, 47, and 43 kDa. By immunohistochemistry, both NMB and NMB-R were expressed in normal and cancerous colonic epithelial tissues. In cancer, the amount of NMB was similar to that expressed by proliferating epithelial cells located within the crypt. In contrast, NMB-R expression was increased in cancer, with higher levels detected in better differentiated tumor cells. To assess NMB function, proliferation was determined in the nonmalignant human colonic epithelial cell line NCM-460 and in the colon cancer cell lines Caco-2 and HT-29. Exogenously added NMB was 50-100% more efficacious than gastrin-releasing peptide in causing tumor cell proliferation, whereas only NMB increased NCM-460 cell proliferation. These findings indicate that NMB and its receptor are coexpressed by proliferating cells in which they act in an autocrine fashion with similar and modest potency in both normal and malignant colonic epithelial cells.

[1]  M. Moyer,et al.  NCM460, a normal human colon mucosal epithelial cell line , 1996, In Vitro Cellular & Developmental Biology - Animal.

[2]  R. Benya,et al.  Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin‐releasing peptide's morphogenic properties , 2004, Journal of cellular physiology.

[3]  B. Yeğen Bombesin-like peptides: candidates as diagnostic and therapeutic tools. , 2003, Current pharmaceutical design.

[4]  Randal Cox,et al.  Quantitative Immunohistochemistry by Measuring Cumulative Signal Strength Accurately Measures Receptor Number , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  R. Jensen,et al.  Neuropeptides as autocrine growth factors in cancer cells. , 2003, Current pharmaceutical design.

[6]  G. Rubin,et al.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Wada,et al.  Restraint stress impaired maternal behavior in female mice lacking the neuromedin B receptor (NMB-R) gene , 2002, Neuroscience Letters.

[8]  K. Wada,et al.  Decreased marble burying behavior in female mice lacking neuromedin-B receptor (NMB-R) implies the involvement of NMB/NMB-R in 5-HT neuron function , 2002, Brain Research.

[9]  K. Wada,et al.  Bombesin and its family of peptides: prospects for the treatment of obesity. , 2002, European journal of pharmacology.

[10]  K. Wada,et al.  Role of bombesin (BN)-like peptides/receptors in emotional behavior by comparison of three strains of BN-like peptide receptor knockout mice , 2002, Molecular Psychiatry.

[11]  G. Cassano,et al.  The proliferative response of HT-29 human colon adenocarcinoma cells to bombesin-like peptides. , 2001, Cancer letters.

[12]  T. Gress,et al.  GRP-receptor-mediated signal transduction, gene expression and DNA synthesis in the human pancreatic adenocarcinoma cell line HPAF , 2001, Peptides.

[13]  R. Benya,et al.  The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer , 2001, Peptides.

[14]  A. Schally,et al.  The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers , 2000, Regulatory Peptides.

[15]  A. Schally,et al.  Presence of receptors for bombesin/gastrin‐releasing peptide and mRNA for three receptor subtypes in human prostate cancers , 2000, The Prostate.

[16]  K A Matkowskyj,et al.  Quantitative Immunohistochemistry by Measuring Cumulative Signal Strength Using Commercially Available Software Photoshop and Matlab , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  J. Primrose,et al.  Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa , 1999, British Journal of Cancer.

[18]  R. Benya,et al.  Gastrin-releasing Peptide Is a Mitogen and a Morphogen in Murine Colon Cancer 1 , 2000 .

[19]  J C Reubi,et al.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. , 1999, The American journal of pathology.

[20]  J. Siegfried,et al.  Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. , 1999, Pulmonary pharmacology & therapeutics.

[21]  R. Benya,et al.  Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. , 1999, The American journal of physiology.

[22]  P. Troncoso,et al.  In situ hybridization for gastrin‐releasing peptide receptor (GRP receptor) expression in prostatic carcinoma , 1998, International journal of cancer.

[23]  R. Jensen,et al.  Neuromedin B receptor activation causes tyrosine phosphorylation of p125FAK by a phospholipase C independent mechanism which requires p21rho and integrity of the actin cytoskeleton. , 1997, Biochemistry.

[24]  R. Jensen,et al.  Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates That It Has a Unique Pharmacology Compared with Other Mammalian Bombesin Receptors* , 1997, The Journal of Biological Chemistry.

[25]  G. Nussdorfer,et al.  The role of neuromedin B in the regulation of rat pituitary-adrenocortical function. , 1996, Histology and histopathology.

[26]  S. O’Grady,et al.  Regulation of colonic ion transport by GRP. II. GRP modulates the epithelial response to PGE2. , 1996, The American journal of physiology.

[27]  S. O’Grady,et al.  Regulation of colonic ion transport by GRP. I. GRP stimulates transepithelial K and Na secretion. , 1996, The American journal of physiology.

[28]  R. Jensen,et al.  Expression and characterization of cloned human bombesin receptors. , 1995, Molecular pharmacology.

[29]  R. Jensen,et al.  Glycosylation of bombesin receptors: characterization, effect on binding, and G-protein coupling. , 1994, Biochemistry.

[30]  Á. Hernanz,et al.  Stimulation of natural killer and antibody-dependent cellular cytotoxicity activities in mouse leukocytes by bombesin, gastrin-releasing peptide and neuromedin C: Involvement of cyclic AMP, inositol 1,4,5-trisphosphate and protein kinase C , 1993, Journal of Neuroimmunology.

[31]  R. Freshney,et al.  Induction of phenotypic changes in SCLC cell lines in vitro by hexamethylene bisacetamide, sodium butyrate, and cyclic AMP. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Jensen,et al.  Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes. , 1993, Molecular pharmacology.

[33]  R. Jensen,et al.  Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. , 1992, Molecular pharmacology.

[34]  R. Jensen,et al.  Development of a potent bombesin receptor antagonist with prolonged in vivo inhibitory activity on bombesin-stimulated amylase and protein release in the rat , 1992, Peptides.

[35]  J. Battey,et al.  Neuromedin B is present in lung cancer cell lines. , 1992, Cancer research.

[36]  J. Polak,et al.  Role of neuromedin B in control of the release of thyrotropin in hypothyroid and hyperthyroid rats. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Gazdar,et al.  Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells. , 1992, Cancer research.

[38]  R. Jensen,et al.  Systematic development of bombesin/gastrin-releasing peptide antagonists. , 1992, Journal of the National Cancer Institute. Monographs.

[39]  N. Bleehen,et al.  Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. , 1991, Cancer research.

[40]  R. Jensen,et al.  cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor , 1991, Neuron.

[41]  J. Abita,et al.  Characterization, in some human breast cancer cell lines, of gastrin‐releasing peptide‐like receptors which are absent in normal breast epithelial cells , 1990, International journal of cancer.

[42]  R. Jensen,et al.  Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptors. , 1989, The American journal of physiology.

[43]  V. Erspamer Discovery, Isolation, and Characterization of Bombesin‐like Peptides , 1988 .